A BLOCKBUSTER DRUG CANDIDATE FOR DEVASTATING RARE SKIN DISEASES:

PCIll for Pemphigus and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Investor-Focused Webinar: Unlocking the Potential of a Blockbuster Drug for Rare Skin Diseases

Scinai Immunotherapeutics and Pincell are hosting an exclusive live webinar exploring PC111 — a novel drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).

MAY 7, 2025

11:30 AM EST

What we’ll cover at the Event

Challenges in Rare Skin Disease Care

The current treatment landscape and background on the challenges those battling rare skin diseases face

Targeting Critical Gaps in Rare Skin Disorders

The commercial opportunity for PC111 targeting Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)

Expert Perspectives on the Dermatology Market

Insights on the Dermatology Market from Experts in pharmaceutical R&D, Biotech, and Clinical Practice

Meet the Speakers

Amir Reichman

CEO, Scinai Immunotherapeutics

Prof. Carlo Pincelli, MD

Co-founder & CMO, Pincell

Dr. Antonino Amato, MD

Chairman & CEO, Pincell

Dr. Jonathan Sadeh, MD

Scinai Advisory Board; CMO, Bausch Health R&D

Prof. Michael Schön, MD

Scinai Advisory Board; Dept. Head, Dermatology UMG

ABOUT US

ELEVATING DRUG DEVELOPMENT. EVERY STEP OF THE WAY

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases.

With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody pipeline targeting diseases with large unmet medical needs.